Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Pulmonary Hypertension, January 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 109 articles: HTML format

Single Articles

1. LIU C, Lu JW, Wu CH, Ho YJ, et al
   Adjuvant Molecular Hydrogen Therapy in SLE-associated Pulmonary Arterial Hypertension: A Case Report on Immunomodulatory Effects on Regulatory and Effector Lymphocytes.
   In Vivo. 2026;40:551-560.
   Abstract
   
   
2. XU W, Shen Y, Wan Z, Guo J, et al
   Macrophage-driven immunopathology in pulmonary arterial hypertension: from mechanisms to targeted therapies.
   Front Immunol. 2025;16:1721071.
   Abstract
   
   
3. FERRARA F, Castaldo R, Gargani L, Benjamin N, et al
   Predicting Exercise Pulmonary Hypertension: The RIGHT-NET Machine Learning model A Pilot Study.
   Transl Res. 2025 Dec 30:S1931-5244(25)00121-5. doi: 10.1016/j.trsl.2025.
   Abstract
   
   
4. DESHMUKH SN, Anand A, Deore SS
   Haemodynamics and post-exercise recovery response in chronic obstructive pulmonary disease-pulmonary hypertension and interstitial lung disease-pulmonary hypertension: An appraisal.
   Lung India. 2026;43:105-106.
   Abstract
   
   
5. MALAKOUTIKHAH M, Kalantari F, Nematollahi A, Moradi H, et al
   Severe pulmonary hypertension associated with unilateral pulmonary artery hypoplasia: A case report.
   ARYA Atheroscler. 2025;21:1-7.
   Abstract
   
   
6. MARTINEZ-SOLANO J, Bermejo-Fernandez J, Gonzalez-Mansilla A, Garcia-Orta R, et al
   The role of the bone morphogenetic protein receptor 2 pathway in group 2 pulmonary hypertension secondary to valvular heart disease.
   ERJ Open Res. 2025;11:00543-2025.
   Abstract
   
   
7. J JB, R J, Murugan S, G SL, et al
   Identification of upregulated genes in pulmonary hypertension using RNA sequencing profiling.
   Bioinformation. 2025;21:3105-3109.
   Abstract
   
   
8. TITZ A, Muller J, Schneider SR, Lichtblau M, et al
   Comparison of Invasive Versus Non-Invasive Pulse Contour-Based Cardiac Output Measurements at Rest and During Exercise in Pulmonary Hypertension.
   J Clin Med. 2025;14:8971.
   Abstract
   
   
9. TITOLO AC, Ferrocino M, Biagi E, Rizzo L, et al
   Neonatologist-Performed Echocardiography in Neonatal Pulmonary Hypertension: A Narrative Review of the Literature.
   Diagnostics (Basel). 2025;15:3154.
   Abstract
   
   
10. HUANG W, Zheng R, Gong L, Zhang Y, et al
    Roles of Lipid Metabolism in Pulmonary Hypertension: Friend or Foe?
    Biomolecules. 2025;15:1679.
    Abstract
    
    
11. CSOMA B, Szucs G, Bikov A, Rozgonyi ZD, et al
    Alveolar and Bronchial Nitric Oxide Parameters in Pre-Capillary Pulmonary Hypertension.
    Biomedicines. 2025;13:2957.
    Abstract
    
    
12. WANG M, Lu J, Li X, Xie H, et al
    Construction of an early diagnostic model for pulmonary hypertension based on aging-related signature genes and identification of potential therapeutic targets.
    Sci Rep. 2025;15:44788.
    Abstract
    
    
13. LARSON J, Khorasani S, Laurenzo S, Chiu S, et al
    Leveraging Vascular Over Ventricular Ratios in Observational Chronic Thromboembolic Pulmonary Hypertension and Acute Pulmonary Embolism Cohorts to Decode Clot Chronicity on Computed Tomography Angiography.
    Pulm Circ. 2025;15:e70223.
    Abstract
    
    
14. SANTACRUZ JC, Mantilla MJ, Pulido S, Agudelo C, et al
    Pulmonary Hypertension in Systemic Lupus Erythematosus: Current Evidence and Future Directions.
    Cureus. 2025;17:e97863.
    Abstract
    
    
15. YAGDIRAN B, Uchehara CU, Safak A, Cekmen N, et al
    The relationship between preoperative pulmonary hypertension risk in liver transplant and vascular and biliary complications in the postoperative period.
    Diagn Interv Radiol. 2025 Dec 29. doi: 10.4274/dir.2025.253707.
    Abstract
    
    
16. PARLAK ES, Uzun BAA, Gungor K, Ceylan EG, et al
    Evaluation of Predisposing Factors and Coexisting Diseases in the Development of Chronic Thromboembolic Pulmonary Disease.
    Clin Respir J. 2025;19:e70147.
    Abstract
    
    
17. LIU Y, Deng X, He C, Lv S, et al
    NDRG1-HIF1alpha interaction in hypoxic signaling for pulmonary hypertension.
    Int J Biol Macromol. 2025;339.
    Abstract
    
    
18. DUBLE EH, Springer CM, Koster LS
    Association of pulmonary arterial end-diastolic forward flow and right heart remodeling in dogs with congenital pulmonic stenosis and precapillary pulmonary hypertension.
    J Vet Cardiol. 2025;64:14-24.
    Abstract
    
    
19. DZIKOWSKA-DIDUCH O, Dudzik-Niewiadomska I, Kurnicka K, Lichodziejewska B, et al
    Elevated tricuspid peak systolic gradient with enlarged right ventricle present during acute episode of pulmonary embolism predict subsequent chronic thromboembolic pulmonary hypertension.
    Thromb J. 2025 Dec 27. doi: 10.1186/s12959-025-00818.
    Abstract
    
    
20. JU G, Zhang S, Zhang J, Dong F, et al
    Sodium Houttuyfonate Alleviates Monocrotaline-induced Pulmonary Hypertension by Regulating Canonical Transient Receptor Potential Channel Proteins.
    Eur J Pharmacol. 2025 Dec 25:178507. doi: 10.1016/j.ejphar.2025.178507.
    Abstract
    
    
21. HE R, Liu J, Tang X, Liu H, et al
    Reversible Pulmonary Hypertension in CblC Deficiency (MMACHC c.80 A>G): long-term outcomes of metabolic and PH-targeted therapy.
    Pediatr Res. 2025 Dec 26. doi: 10.1038/s41390-025-04720.
    Abstract
    
    
22. ZHANG Y, Zhang Y, Yang S, Huang Y, et al
    Risk prediction and therapeutic targets for incident pulmonary hypertension: a large-scale proteomic profiling and Mendelian randomization study.
    Front Med. 2025 Dec 27. doi: 10.1007/s11684-025-1183.
    Abstract
    
    
23. BUSCHULTE K, Kabitz HJ, Hagmeyer L, Hammerl P, et al
    Baseline characteristics from the EXCITING-ILD registry.
    BMJ Open Respir Res. 2025;12:e002902.
    Abstract
    
    
24. CHEN M, He Y, Zhu X, Luo Y, et al
    Baicalin attenuates pulmonary hypertension by targeting AMPK/CPT1A-mediated fatty acid metabolism.
    Phytomedicine. 2025;150:157703.
    Abstract
    
    
25. SONNICK MA, Laothamatas KC, Anderson MR, Stewart D, et al
    Waitlist outcome differences for pulmonary hypertension patients are worse in the CAS era.
    JHLT Open. 2025;11:100443.
    Abstract
    
    
26. MACIAS PRADO FE, German Gaibor JM, Portaluppi Cervantes RE, Campozano Burgos MA, et al
    Beyond Childhood: Percutaneous Closure of an Aortopulmonary Window with Severe Pulmonary Hypertension in an Adult Woman - A Case Report.
    Interv Cardiol. 2025;20:e34.
    Abstract
    
    
27. BEN DAVID R, Gurfinkel R, Nalbandyan K, Roth I, et al
    [Pulmonary Tumor Thrombotic Microangiopathy - Case Report].
    Harefuah. 2025;165:647-650.
    Abstract
    
    
28. KERRIGAN WJ, Church AC, Herrick AL
    Systemic Sclerosis-Recent Advances in Diagnosis and Management.
    Br J Hosp Med (Lond). 2025;86:1-21.
    Abstract
    
    
29. FUJIWARA M, Yamamura A, Miyaki R, Amano T, et al
    Enhanced Yoda1-induced vasoconstriction in pulmonary arterial smooth muscle from monocrotaline-induced pulmonary hypertensive rats.
    Biochem Biophys Res Commun. 2025;797:153183.
    Abstract
    
    
30. NEWMAN J, Ghani H, Munagala S, Otter E, et al
    The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients.
    ERJ Open Res. 2025;11:00297-2025.
    Abstract
    
    
31. GILLMEYER KR
    Insights from the Pulmonary Hypertension Global Patient Survey: challenges in pulmonary hypertension care abound but so do opportunities.
    ERJ Open Res. 2025;11:00963-2025.
    Abstract
    
    
32. JENKIN I, Dimopoulos K, Nathan SD, Herbert S, et al
    Survival in patients with pulmonary hypertension associated with fibrotic interstitial lung disease (ILD) is independent of ILD subtype.
    ERJ Open Res. 2025;11:00235-2025.
    Abstract
    
    
33. MICKAEL C, Kabwe JC, Fonseca Balladares D, Bai AS, et al
    Pulmonary Hypertension Associated With Sickle Cell Disease and Schistosomiasis.
    Pulm Circ. 2025;15:e70230.
    Abstract
    
    
34. LOKHANDWALA A, Salman Al-Timimi A, Da Silva T, Nourouzpour S, et al
    Clinical implications of frailty in hospitalized patients with pulmonary arterial hypertension.
    Chron Respir Dis. 2025;22:14799731251408844.
    Abstract
    
    
35. DAGHER C, Akiki M, Swanson K, Carollo B, et al
    Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy.
    Clin Respir J. 2025;19:e70149.
    Abstract
    
    
36. TAKITA Y, Morishita J, Park S, Goda A, et al
    Mindfulness-Based Self-Management Program Using a Mobile Application for Patients with Pulmonary Hypertension: A Single-Arm Feasibility Study.
    JMIR Cardio. 2025 Dec 16. doi: 10.2196/79639.
    Abstract
    
    
37. WANG X, He Y, Li K, Xue Z, et al
    TRAF6 mediates vascular remodeling via endoplasmic reticulum stress-mitophagy in hypoxic pulmonary hypertension.
    Free Radic Biol Med. 2025 Dec 20:S0891-5849(25)01448.
    Abstract
    
    
38. BEIS I, Dipla K, Haidich AB, Boutou A, et al
    Safety and efficacy of exercise training in patients with pulmonary hypertension: a systematic review and meta-analysis.
    Eur J Appl Physiol. 2025 Dec 22. doi: 10.1007/s00421-025-06104.
    Abstract
    
    
39. SEEGER W
    The Discovery of Inhaled Prostanoids for Pulmonary Hypertension.
    Pulm Circ. 2025;15:e70192.
    Abstract
    
    
40. LEE L, Cao S, Miles CB, Troy MP, et al
    Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension: Patient Selection, Procedural Pearls, and Expected Outcomes.
    Semin Intervent Radiol. 2025;42:509-517.
    Abstract
    
    
41. MERK J, Yung D, Wright JN, Kapur RP, et al
    Noncirrhotic Portopulmonary Hypertension Due to Hepatoportal Sclerosis in Adams-Oliver Syndrome.
    Pediatrics. 2026;157:e2025073243.
    Abstract
    
    
42. HU Y, Wang Y, Tan W, Zhao C, et al
    Design and Optimization of LOXL2 and sGC Dual-Target Regulators Targeting Extracellular Matrix Dysregulation and Vasodilation for the Treatment of Pulmonary Arterial Hypertension.
    J Med Chem. 2025;68:26547-26573.
    Abstract
    
    
43. ZULFIQAR H, Alali J, Granlund B, Feng J, et al
    Interleukin-35 alleviates pulmonary arterial hypertension by suppressing the VEGFA/VEGFR2 signaling pathway.
    Life Sci. 2026;385:124144.
    Abstract
    
    
44. ZHANG JY, Zhang R, Liu J, Chen L, et al
    Agomelatine alleviates hypoxia-induced pulmonary arterial hypertension by activating mitophagy via the SIRT1/FoxO1/ULK1 signaling pathway.
    Biochem Pharmacol. 2026;244:117624.
    Abstract
    
    
45. WANG S, Song S, Feng H, Sun H, et al
    tRF-31-PS5P4PW3FJHP inhibits hypoxia-induced proliferation of pulmonary artery endothelial cells by regulating EDN1 splicing via binding to LSM4.
    Eur J Pharmacol. 2026;1011:178426.
    Abstract
    
    
46. ZOLTY R
    Antiproliferative therapies in pulmonary arterial hypertension.
    Expert Opin Pharmacother. 2025;26:1895-1911.
    Abstract
    
    
47. AHMAD A, Zhang S, Ren Q, Li L, et al
    Transthoracic echocardiography of left ventricular underfilling improves risk stratification in pulmonary arterial hypertension.
    Sci Rep. 2025;15:45718.
    Abstract
    
    
48. MOSS ME, Smit MC, Klouda T, Zhao Z, et al
    Pericytes and Lung Vascular Remodeling.
    Arterioscler Thromb Vasc Biol. 2026;46:17-26.
    Abstract
    
    
49. GARCIA KM, Hardie BA, Valdez-Jasso D
    Sex-Specific Interventricular Septum Mechanics in Pulmonary Arterial Hypertension.
    Ann Biomed Eng. 2026;54:29-40.
    Abstract
    
    
50. BETTER J, Leroy S, Ninaber MK, Trakada G, et al
    VE/VCO(2) at ventilatory threshold and peak VO(2) in CPET studies of patients with scleroderma-associated PAH: A systematic review and meta-analyses.
    Autoimmun Rev. 2026;25:103942.
    Abstract
    
    
51. SHI W, Chen L, Zhang W, He P, et al
    YAP-mediated glycolysis promotes pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension.
    J Biol Chem. 2025;301:110836.
    Abstract
    
    
52. HUANG Y, Zhang C, Ye H, Sun X, et al
    A Noninvasive Prognostic Model for Pulmonary Arterial Hypertension Associated With Connective Tissue Diseases Based on Multislice Chest Computed Tomography Parameters.
    J Thorac Imaging. 2026;41:e0855.
    Abstract
    
    
53. ZHOU L, Luo J, Tan C, Li Y, et al
    Worldwide Burden of Pulmonary Arterial Hypertension in Adults Aged 65 Years and Older From 1990 to 2021.
    J Am Geriatr Soc. 2025;73:3700-3707.
    Abstract
    
    
54. TRUONG R, Davis S, Rosario N, Wollen J, et al
    Sotatercept: A New Frontier in Pulmonary Arterial Hypertension Treatment.
    Ann Pharmacother. 2026;60:163-174.
    Abstract
    
    
55. POST TE, Denney C, Cohen A, Jordan J, et al
    Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research.
    Br J Clin Pharmacol. 2026;92:58-72.
    Abstract
    
    
56. AKOPYAN K, Peterson J, Amoda O, Khasawneh M, et al
    Echocardiographic Pulmonary Hypertension in Patients Positive for Myositis-Specific and Myositis-Associated Antibodies.
    J Clin Med. 2025;15:77.
    Abstract
    
    
57. KOOK H, Kim W, Heo R, Kim K, et al
    Current Perspectives on Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension.
    J Clin Med. 2025;15:51.
    Abstract
    
    
58. ZHANG X, Chen M, Wang R, Liu R, et al
    Flavonoids: Potential New Drug Candidates for Attenuating Vascular Remodeling in Pulmonary Hypertension.
    Int J Mol Sci. 2025;27:210.
    Abstract
    
    
59. IANCU DG, Cristescu L, Mares RG, Varga A, et al
    Reply to Pagnoni et al. Clarifying the Clinical Utility of NTAR/RGR for PAH and CTEPH. Comment on "Iancu et al. Evaluating NT-proBNP-to-Albumin (NTAR) and RDW-to-eGFR (RGR) Ratios as Biomarkers for Predicting Hospitalization Duration and Mortality in
    Diagnostics (Basel). 2025;16:56.
    Abstract
    
    
60. PAGNONI G, Vicenzi A, Coppi F
    Clarifying the Clinical Utility of NTAR/RGR for PAH and CTEPH. Comment on Iancu et al. Evaluating NT-proBNP-to-Albumin (NTAR) and RDW-to-eGFR (RGR) Ratios as Biomarkers for Predicting Hospitalization Duration and Mortality in Pulmonary Arterial Hypert
    Diagnostics (Basel). 2025;16:55.
    Abstract
    
    
61. ADU-AMANKWAAH J, Shi Y, Song H, Ma Y, et al
    Correction: Signaling pathways and targeted therapy for pulmonary hypertension.
    Signal Transduct Target Ther. 2026;11:12.
    Abstract
    
    
62. ZHANG Y, Ye J, Chen J, Chen J, et al
    Pharmacovigilance Analysis of Sotatercept for the Treatment of Pulmonary Arterial Hypertension Based on FAERS Database.
    Cardiovasc Toxicol. 2026;26:12.
    Abstract
    
    
63. VACHRUSHEV NS, Karpov AA, Shilenko LA, Vaulina DD, et al
    Lung Tissue RNA Sequencing Shows Dysregulation of the Bronchial Epithelium in a Rat Model of Chronic Thromboembolic Pulmonary Hypertension.
    Bull Exp Biol Med. 2026 Jan 9. doi: 10.1007/s10517-026-06549.
    Abstract
    
    
64. PRISCO SZ, Kantorovich A, Liu Y, Sahay S, et al
    Global Resource Disparities Between Pulmonary Hypertension Centers: Results From the International Survey by the PVRI IDDI Access to Care Workstream.
    Pulm Circ. 2026;16:e70229.
    Abstract
    
    
65. DAOUD A, Lopez PP, Mombeini H, Zaeske A, et al
    Echocardiographic Deformation Imaging of the Right Atrium: A New Paradigm in Noninvasive Hemodynamic Assessment.
    Curr Cardiol Rep. 2026;28:11.
    Abstract
    
    
66. KHAN SA, Parikh T, Rao A, Agrawal A, et al
    In-hospital Mortality Patterns and Readmissions in Patients With Chronic Obstructive Pulmonary Disease: An Analysis of the Role of Pulmonary Hypertension.
    COPD. 2026;23:2582902.
    Abstract
    
    
67. SHIMOJO T, Tada T, Ito H, Kinoshita H, et al
    Pulmonary tumour thrombotic microangiopathy or chronic thromboembolic pulmonary hypertension?-diagnosed by pulmonary wedge aspiration cytology using a Swan-Ganz catheter: a case report.
    Eur Heart J Case Rep. 2025;10:ytaf648.
    Abstract
    
    
68. ZHU Y, He J, Cai M, Wen L, et al
    Safety of a novel portable inhaled nitric oxide generator for therapy of persistent pulmonary hypertension in neonates: a case series study.
    Transl Pediatr. 2025;14:3305-3317.
    Abstract
    
    
69. MIRZAMOHAMMADI S, Shirazi N, Deravi N, Zadeh RH, et al
    Coronary Artery Calcium Score as a Potential Non-Invasive Marker for Pulmonary Artery Hypertension.
    Acta Med Indones. 2025;57:445-453.
    Abstract
    
    
70. WANG X, Song X, Yu F, Yu Y, et al
    A Superoxide Anion-Responsive NIR Fluorogenic Probe Unravels Aucubin's Dual-Axis Therapeutic Mechanism in Hypoxic Pulmonary Hypertension via Ferroptosis Suppression and Oxidative Injury Mitigation.
    Anal Chem. 2026 Jan 7. doi: 10.1021/acs.analchem.5c05233.
    Abstract
    
    
71. KONDOH Y, Ogura T, Nishiyama O, Kinoshita H, et al
    Corrigendum to "Long-term effects of inhaled treprostinil in Japanese patients with pulmonary hypertension associated with interstitial lung disease" [Respir Invest, Volume 64, Issue 1, January 2026, 101340].
    Respir Investig. 2026 Jan 6:101365. doi: 10.1016/j.resinv.2025.101365.
    Abstract
    
    
72. SEERAM VK, Boppana LKT
    Unilateral absence of pulmonary artery presenting with pulmonary hypertension in two adults.
    BMJ Case Rep. 2026;19:e269028.
    Abstract
    
    
73. ARTHUR ME, Mudaliar P, Sakharpe A, Odo N, et al
    Between a Rock and a Hard Place: Hip Fracture Repair in an Elderly Patient with Severe Cardiac Comorbidities and Limited Options: A Problem-Based Learning Discussion.
    A A Pract. 2026;20:e02058.
    Abstract
    
    
74. VENKATESHVARAN A, Lindow T, Jumatate R, Kovacs A, et al
    Linking Energetic Inefficiency to Ventriculoarterial Uncoupling in Pulmonary Hypertension.
    Echocardiography. 2026;43:e70389.
    Abstract
    
    
75. HAO J, Fang G, Li X, Wang T, et al
    Targeting Macrophage Crosstalk to PASMC by Blunting Inflammatory Phenotype Via SerpinB1 Protects Against Hypoxia-Induced Pulmonary Hypertension.
    Hypertension. 2026 Jan 7. doi: 10.1161/HYPERTENSIONAHA.125.25832.
    Abstract
    
    
76. HUANG Y, Yan S, Zhu J, Zhang W, et al
    SPP1 May Play an Important Role in the Carcinoid Nature of PAH.
    Mediators Inflamm. 2025;2025:7457106.
    Abstract
    
    
77. PAK O, Weissmann N
    Is it the extracellular matrix?-smooth muscle fate in pulmonary hypertension secondary to left heart disease.
    Cardiovasc Res. 2026 Jan 7:cvaf261. doi: 10.1093.
    Abstract
    
    
78. LI G, Zhao Z, Machitani M, Ishikawa R, et al
    Elucidation of mechanisms underlying the therapeutic effects of cordycepin on pulmonary hypertension, with a focus on cell senescence and gut microbiota.
    Biomed Pharmacother. 2026;194:118923.
    Abstract
    
    
79. YUE K, Qu X, Zhang F, Zhao M, et al
    Pulmonary hypertension caused by fibrosing mediastinitis: A case report and literature review.
    Medicine (Baltimore). 2026;105:e46180.
    Abstract
    
    
80. KIM TH, Youn SE, Chung SH
    Clinical impact of treprostinil in neonates with persistent pulmonary hypertension refractory to inhaled nitric oxide: A retrospective cohort study.
    Medicine (Baltimore). 2026;105:e46984.
    Abstract
    
    
81. BELKIN MN, Fudim M, Baratto C, Grinstein J, et al
    Standardization of Baseline and Provocative Invasive Hemodynamic Protocols for the Evaluation of Heart Failure and Pulmonary Hypertension: A Scientific Statement From the American Heart Association.
    Circ Heart Fail. 2026 Jan 6:e000088. doi: 10.1161/HHF.0000000000000088.
    Abstract
    
    
82. QIU Y, Lyu X, Zhang D, Xu H, et al
    Gut Microbiota in Pulmonary Arterial Hypertension: Murine Models and Human Microbial Signatures, Pathogenic Mechanisms, and Emerging Therapeutic Avenues.
    Compr Physiol. 2026;16:e70094.
    Abstract
    
    
83. WANG Q, Liu J, Li R, Kong S, et al
    Macrophage kappa-opioid receptor inhibits hypoxic pulmonary hypertension progression and right heart dysfunction via an SCD1-dependent anti-inflammatory response.
    Genes Dis. 2025;13:101604.
    Abstract
    
    
84. WANG M, Zhang M, Chen J, Wang Y, et al
    Nuclear SIRT6 depletion activates LINE1-cGAS-STING pathway to induce PASMCs senescence in hypoxic pulmonary hypertension.
    Cell Signal. 2026;139:112351.
    Abstract
    
    
85. DING H, Zeng M, Sun B, Deng F, et al
    Measurement of Pulmonary Artery Pressure in Rats Using Right Heart Catheterization.
    J Vis Exp. 2025;.
    Abstract
    
    
86. BAHMANI F, Pearce D, Southern K, Nwadiaro K, et al
    Fluid Flow Analysis of Pulmonary Hypertension in End Stage Renal Disease: A NAMS-Driven Case Study.
    J Biomech Eng. 2026 Jan 5:1-29. doi: 10.1115/1.4070760.
    Abstract
    
    
87. HEGAZY Y, Abdallah A, Salem A, Assaker A, et al
    When the Skin Tells a Pulmonary Story: A Case of Neurofibromatosis Type 1-Associated Pulmonary Hypertension.
    Cureus. 2025;17:e98338.
    Abstract
    
    
88. KURAHARA LH
    [Cellular senescence in pulmonary hypertension].
    Nihon Yakurigaku Zasshi. 2026;161:55-56.
    Abstract
    
    
89. YOKOKAWA T, Nishiura K, Akama J, Kiko T, et al
    Significance of 14-3-3 Epsilon for Right Ventricular Failure Associated with Pulmonary Hypertension.
    Intern Med. 2026 Jan 2. doi: 10.2169/internalmedicine.6383.
    Abstract
    
    
90. NAEEM A, Bolaji O, Kidess GG, Fahed J, et al
    Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up.
    Int J Cardiol. 2026;447:134150.
    Abstract
    
    
91. SOMECH J, Zahler D, St-Germain R, Roshdy O, et al
    Rapidly reversible precapillary pulmonary hypertension in a patient with scurvy.
    Can J Cardiol. 2026 Jan 2:S0828-282X(25)01621-6. doi: 10.1016/j.cjca.2025.
    Abstract
    
    
92. BARANYAI T, Takacs P, Szabo B, Nagy Z, et al
    [Balloon pulmonary angioplasty in Gottsegen National Cardiovascular Center - results of the first 2 years].
    Orv Hetil. 2026;167:23-29.
    Abstract
    
    
93. ROSHANZAMIR Z, Mohammadi F, Shirzadi R
    Pulmonary hypertension in pediatric patients with cystic fibrosis during acute pulmonary exacerbations: prevalence and associated factors.
    BMC Pulm Med. 2026 Jan 3. doi: 10.1186/s12890-025-04095.
    Abstract
    
    
94. KAM THH, Kam KKH, Wong MKL, Yan BPY, et al
    Haemodynamic and clinical impacts of switching phosphodiesterase-5 inhibitors to riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH) after balloon pulmonary angioplasty (BPA) - a prospective cohort study.
    BMC Pulm Med. 2026 Jan 3. doi: 10.1186/s12890-025-04069.
    Abstract
    
    
95. HAN R, Wang Y, Lu X, Li W, et al
    Comprehensive profiling of lactylation-associated genes in pulmonary hypertension through bulk and single-cell RNA sequencing integration.
    Respir Res. 2026 Jan 3. doi: 10.1186/s12931-025-03446.
    Abstract
    
    
96. GUAN A, Dai Z, Lin J, Chen Q, et al
    Global disease burden of pulmonary arterial hypertension: patterns and inequality in 1990-2021, with projections to 2035.
    BMC Public Health. 2026;26:4.
    Abstract
    
    
97. LIU BY, Xie M
    [Application and research progress of artificial intelligence in the diagnosis and treatment of rare lung diseases].
    Zhonghua Jie He He Hu Xi Za Zhi. 2026;49:78-83.
    Abstract
    
    
98. MIHAI A
    Right Ventricular Global Wasted Work and RV-PA Coupling: Implications for Pulmonary Hypertension.
    Echocardiography. 2026;43:e70384.
    Abstract
    
    
99. SPAGNOLO P, Dhanani Z, Cameli P, Fiorentu G, et al
    Advanced Pulmonary Sarcoidosis.
    Semin Respir Crit Care Med. 2025;46:564-575.
    Abstract
    
    
100. QIAO X, Su D, Qin S, Shang L, et al
     Pulmonary arterial hypertension increases the risk of female sexual dysfunction: a systematic review and meta-analysis.
     J Sex Med. 2026;23:qdaf294.
     Abstract
     
     
101. ZHI C, Shi X, Chen S, Cai Z, et al
     Single-cell transcriptome analysis reveals critical causative candidates for Down syndrome-related lung diseases.
     J Genet Genomics. 2026;53:75-86.
     Abstract
     
     
102. YANG JZ, Madani MM, Papamatheakis DG, Fernandes TM, et al
     CHEST How I Do It: Management of chronic thromboembolic pulmonary hypertension before and after pulmonary thromboendarterectomy.
     Chest. 2026 Jan 2:S0012-3692(25)05963-X. doi: 10.1016/j.chest.2025.
     Abstract
     
     
103. ZAFEIROPOULOS S, Ahmed U, Bekiaridou A, Jayaprakash N, et al
     Correction to: Ultrasound Neuromodulation of an Anti-Inflammatory Pathway at the Spleen Improves Experimental Pulmonary Hypertension.
     Circ Res. 2026;138:e000740.
     Abstract
     
     
104. SHEN Y, Bisserier M
     ADAR1-Mediated RNA Editing Regulates Innate Immunity in Pulmonary Hypertension.
     Circ Res. 2026;138:e327782.
     Abstract
     
     
105. GUO S, Pan T, Yan X, Cheng Y, et al
     Differential Impact of Recruited and Resident Macrophages on Hypoxia-Induced Pulmonary Hypertension.
     Circ Res. 2025 Dec 31. doi: 10.1161/CIRCRESAHA.125.326472.
     Abstract
     
     
106. OLLOSU M, Tripodi VF, Aresu C, Ledda G, et al
     Efficacy and Safety of Pulmonary Vasodilator and Inodilator Drugs in Congenital Heart Disease Surgery: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
     J Cardiothorac Vasc Anesth. 2026;40:333-346.
     Abstract
     
     
107. SHIGEMURA N, Hage CA
     Reframing Surgical Decision-Making When Treating Severe Pulmonary Hypertension: Beyond the Binary of Lungs Alone versus Combined Heart-Lung Transplantation.
     J Heart Lung Transplant. 2025 Dec 20:S1053-2498(25)02466.
     Abstract
     
     
108. MINATSUKI S, Hatano M, Funakoshi K, Taniguchi Y, et al
     Significance of diffusing capacity of the lungs for carbon monoxide on chronic thromboembolic pulmonary hypertension.
     Thorax. 2026 Jan 7:thorax-2025-223670. doi: 10.1136/thorax-2025-223670.
     Abstract
     
     
109. WU C, Wang Z, Luo Y, Sun H, et al
     Global, regional, and national burden of pulmonary arterial hypertension from 1990 to 2021 and projection to 2050: A systematic analysis for the global burden of disease study 2021.
     PLoS One. 2025;20:e0338335.
     Abstract